Literature DB >> 12617191

Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas.

K Saito1, M Kato, N Susaki, T Nagatani, T Nagasaka, J Yoshida.   

Abstract

Neurofibromatosis type 2 (NF2) is a formidable disease with considerable morbidity. Among tumors associated with NF2, schwannomas are the most difficult to treat because they are multiple and tend to recur. Vascular endothelial growth factor (VEGF) has been reported to act as a survival factor for Schwann cells. We, therefore, investigated VEGF expression in NF2-associated and sporadic schwannomas. We also evaluated the proliferative potential of these tumors by Ki-67 staining (MIB-1 labeling index) and microvascular density by CD34 staining. Immunohistochemistry was performed in 8 schwannomas from 6 NF2 patients, 2 schwannomas from 2 probable NF2 patients and 10 sporadic schwannomas. VEGF immunostaining was present in most schwannomas: all sporadic schwannomas and 8 of 10 schwannomas from NF2 or probable NF2 patients (NF2 group). No difference was evident in VEGF staining between the 2 groups. MIB-1 labeling index was significantly higher in the NF2 group (3.8 +/- 1.7) than the sporadic group (2.0 +/- 1.0, p < 0.01). Microvascular density was higher in the NF2 group (12.9 +/- 6.0) than the sporadic group (9.4 +/- 3.5), but not significantly (p = 0.06). Although VEGF alone cannot explain the higher proliferative potential in NF2-associated schwannomas, VEGF could be a factor influencing the proliferative potential of schwannomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12617191

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  8 in total

1.  Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2.

Authors:  Matthieu Peyre; Stephane Goutagny; Sandrine Imbeaud; Alexis Bozorg-Grayeli; Michele Felce; Olivier Sterkers; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2011-07-28       Impact factor: 12.300

2.  The fate of spinal schwannomas following subtotal resection: a retrospective multicenter study by the Korea spinal oncology research group.

Authors:  Seil Sohn; Chun Kee Chung; Sung-Hye Park; Eun-Sang Kim; Ki-Jeong Kim; Chi Heon Kim
Journal:  J Neurooncol       Date:  2013-06-30       Impact factor: 4.130

3.  Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.

Authors:  Scott R Plotkin; Anat O Stemmer-Rachamimov; Fred G Barker; Chris Halpin; Timothy P Padera; Alex Tyrrell; A Gregory Sorensen; Rakesh K Jain; Emmanuelle di Tomaso
Journal:  N Engl J Med       Date:  2009-07-08       Impact factor: 91.245

4.  Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas.

Authors:  Ryota Tamura; Yukina Morimoto; Mizuto Sato; Yuki Kuranari; Yumiko Oishi; Kenzo Kosugi; Kazunari Yoshida; Masahiro Toda
Journal:  J Neurooncol       Date:  2020-01-03       Impact factor: 4.130

5.  Sporadic Vestibular Schwannoma Size and Location Do not Correlate With the Severity of Hearing Loss at Initial Presentation.

Authors:  Alyssa Brown; Samuel Early; Sasa Vasilijic; Konstantina M Stankovic
Journal:  Front Oncol       Date:  2022-03-15       Impact factor: 6.244

6.  Expression of VEGF and its receptor genes in intracranial schwannomas.

Authors:  Toshio Uesaka; Tadahisa Shono; Satoshi O Suzuki; Akira Nakamizo; Hiroaki Niiro; Masahiro Mizoguchi; Toru Iwaki; Tomio Sasaki
Journal:  J Neurooncol       Date:  2007-02-14       Impact factor: 4.506

7.  Managing NF2-associated vestibular schwannomas in children and young adults: review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality.

Authors:  Isabel Gugel; Julian Zipfel; Philip Hartjen; Lan Kluwe; Marcos Tatagiba; Victor-Felix Mautner; Martin Ulrich Schuhmann
Journal:  Childs Nerv Syst       Date:  2020-06-16       Impact factor: 1.475

8.  Malignant Transformation in Vestibular Schwannoma: Clinical Study With Survival Analysis.

Authors:  Jiuhong Li; Qiguang Wang; Menglan Zhang; Guisheng Zhang; Si Zhang; Xuhui Hui
Journal:  Front Oncol       Date:  2021-04-14       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.